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Abstract
Small interfering (si) RNAs and antisense oligonucleotides (ASOs; here for simplicity reasons, both referred to as
oligonucleotides) are small synthetic RNA or DNA molecules with a sequence complementary to a (pre)mRNA.
Although the basic mechanisms of action between siRNAs and ASO are distinct, a sequence-specific interaction of
the both oligonucleotides with the target (pre)mRNA alters the target’s fate, which includes highly effective
sequence-specific blockade of translation and consequently depletion of the corresponding protein. For a number
of years, these oligonucleotides have been used as a tool in biological research to study gene function in vitro.
More recently, safe and specific delivery of these oligonucleotides to the liver of mammals has been achieved and
optimized. This not only allowed their use for in vivo gene studies in physiology and disease, but also opened the
opportunity for the development of a new generation of RNA-specific drugs for therapeutic purposes. In 2013, the first
oligonucleotide product targeting RNA from the hepatic cholesterol pathway was approved. For blood coagulation, a
large portion of key proteins are produced in the liver, and thereby siRNAs and ASOs can also be used as appropriate
tools to target these proteins in vivo. In this review, we describe the first use of oligonucleotides for this purpose from
zebrafish to primates. As the use of oligonucleotides allows avoidance of early lethality associated with full deficiency
of several coagulation factors, it has proved to be of value for studying these proteins in physiology and disease.
Currently, oligonucleotides are tested as therapeutics, with the ultimate goal to beneficially modulate the hemostatic
balance in thrombosis and hemophilia patients. We discuss both the preclinical and clinical studies of a number of
siRNAs and ASOs with the potential to be introduced as drugs for prophylactic and/or treatment of thrombosis or
hemophilia. We conclude that for the coagulation field, oligonucleotides are of value for research purposes, and now
the moment has come to fulfill their promise as therapeutics.
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Background
Small interfering (si) RNAs and antisense oligonucleotides
(ASOs; here for simplicity reasons, both referred to as
oligonucleotides) are small synthetic RNA or DNA mole-
cules with a sequence complementary to a (pre)mRNA.
Sequence-specific interaction of the siRNA or ASO with
the target (pre)mRNA alters the target’s fate, which
includes sequence-specific blockade of translation and
consequently depletion of the corresponding protein.
siRNAs and ASOs have potential in research and therapy;
design of sequence-specific oligonucleotides and testing
their efficacy in vitro can be relatively easily achieved, and
off-target effects are limited. Moreover, siRNAs and ASOs
have a relatively simple chemistry, malleability, and
delivery (at least in vitro), allowing the oligonucleotides to
become a frequently used tool in biological research for
studying gene function in a variety of eukaryotic cell types.
The major differences between siRNAs and ASOs
comprise differences regarding their chemical structure
and their mode of action, but considering their primary
biological impact i.e., silencing the target (pre)mRNAs
target, both are highly effective [1–3].
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Already in 1978, it was shown that ASOs proved suc-
cessful in targeting (pre)mRNAs in vivo in experimental
animals [4]. More recently, in 2003, also siRNAs showed
strong in vivo potency [5], and delivering siRNAs to the
liver proved feasible and successful [6, 7]. siRNAs and
ASOs both successfully escape degradation in both the
blood circulation and intracellular lysosomes, and effect-
ively reach the appropriate cellular compartment to find
their complementary (pre)mRNA. Hepatic delivery
allowed the use of oligonucleotides for in vivo gene
function studies in normal (hepatic) physiology or for
disease analogues to the in vitro approach. Moreover,
siRNAs and ASOs allow validation of therapeutic targets
in pre-clinical trials forming the stepping stone towards
clinical application [8–10]. As blood coagulation factors
are predominantly expressed in the liver, venous throm-
bosis and hemophilia are diseases that may particularly
benefit from the oligonucleotide approach; both when it
comes to use as a research tool in preclinical research as
well as an approach for therapy.
In this review, we will discuss the possibilities for using
oligonucleotides in venous thrombosis and hemophilia
research and therapy. First, we will outline the chemical
and cellular differences between siRNAs and ASOs.
Next, we will discuss their usefulness to study coagulation
physiology and pathophysiology (i.e., thrombosis and
hemophilia) in animal models. Finally, we will examine
the current status of the exciting first clinical applications
of oligonucleotide approach in venous thrombosis and
hemophilia, and the potentials that come along with this
novel treatment modality.
siRNA and ASO biology and delivery
Although the target of siRNAs and ASOs is the same
i.e., the (pre)mRNA of the gene of interest, their mech-
anism of action is different. In short, siRNAs are
synthetic RNA duplexes consisting of two unmodified
annealed 21-mer oligonucleotides. When siRNAs enter
the cytosol, the antisense strand i.e., the strand which
specifically targets an mRNA, forms a complex with an
endoribonuclease enzyme called Dicer for loading into
RNA-induced silencing complex (RISC), which enables
their stabilization. A single RISC, with the RNase
Argonaute-2 (for which siRNA competes with micro-
RNAs, as discussed in [11]) as its functional unit for ac-
commodating RNA breakdown and the antisense strand
for the specificity, can target and break down multiple
mRNAs in the cytosol. This process is also known as
RNA interference [1, 12]. Whereas siRNAs enter the cell
as a duplex, ASOs are single stranded antisense nucleic
acids (DNA, RNA, or an chemical analogue), typically
8–50 nucleotides long. ASOs are not recognized by
Dicer and not built into RISC upon entering the cytosol;
depending on their chemical modification, they directly
recognize their (pre)mRNA target in the cytosol or
nucleus, due to their complementarity [13]. ASOs can
block, break down (after recruitment of RNase H), or
induce exon skipping of the mRNA [2]. In contrast to siR-
NAs, where a single RISC can degrade multiple mRNAs,
ASOs typically interact with a single (pre)mRNA.
With the desire to use oligonucleotides in vivo, the
delivery to the correct cell and cellular compartment
without being degraded has been an important issue.
Thus far, the delivery of oligonucleotides to the liver in
mammals is an area where significant progress has been
made: siRNAs can be packaged in liposomes with a high
tropism for the liver, and they can be conjugated to
specific ligands (the so called- N-acetylgalactosamine
(GalNAC) ligands, which allows the uptake via hepato-
cyte-specific asialoglycoprotein receptors) which medi-
ate receptor-mediated take-up by hepatocytes [14–17].
A liposome-based formulation and hepatic delivery
has also been described for other oligonucleotides
[18]. Upon systemic delivery, the biodistribution of ASOs
is broad, and the highest concentrations are typically
found in the liver and the kidneys [19–21]. This delivery is
an aspecific process and works via a yet unknown mech-
anism, however it is likely that the relative amphipathic
nature of molecules contribute to this cell-specific distri-
bution. Differences in the delivery of the compound (pack-
aging versus an aspecific process) and the later discovery
of (the functioning of) siRNAs are probably the main rea-
sons why ASOs are ahead for entering into (pre)clinical
trials. More recently, it has been reported recently that
ASOs can alsobe GalNAc conjugated, and that they are
(successfully) tested in (pre)clinical trials [22, 23].
Because the liver appears to be the most successfully
targeted organ thus far - although there are interesting
reports showing e.g., successful delivery of siRNAs to
endothelium and leukocytes [24, 25] - we will focus in this
review on targeting mRNA encoded by genes expressed in
hepatocytes. This successful hepatic delivery of oligonu-
cleotides makes an mRNA-targeting approach specifically
interesting for studies and eventually therapies where a
liver-produced protein is a major contributor to the physi-
ology and/or pathophysiology of a certain disease, such as
hepatitis, hypercholesterolemia, hemophilia, and throm-
bosis [26]. For this review, we will focus solely on the use
of oligonucleotides for targeting liver-produced coagula-
tion proteins, to study their role in biology and modulate
their activity in hemophilia and thrombosis with the
ultimate goal to fight or prevent the disease.
siRNAs and ASOs to study coagulation gene
function in physiology and disease
A conventional approach to study gene function in vivo
is by generating genetically modified animals. Recently,
the developments leading to CRISPR/cas9-mediated
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genome editing have allowed generation of mutant and/
or knockout within a period of months [27]. Neverthe-
less, extensive breeding programs, also for the gener-
ation of proper (littermate) controls, remain expensive,
and gene deletion may preclude detailed study of gene
function due to perinatal lethality or gene redundancy.
Regarding coagulation, most genes from the extrinsic,
common, or anticoagulant pathways have been deleted
in mice, which often resulted in early lethality, mostly as
a result of coagulopathy [28, 29].
As an alternative to the genetic modification approach,
oligonucleotides can be used to transiently silence a gene
of interest. Using oligonucleotides is simple, fast, cheap,
and there are no issues with generating the appropriate
controls, because a group of identical mice can be
injected with a scrambled control sequence, which is
structurally comparable. Moreover, because of the acute
silencing of oligonucleotides, analyses can be performed
before potential compensatory pathways have become
active, and results can be easy translated to other species
(including human), as long as the genome has been
sequenced.
siRNAs and ASOs in animal models for
coagulation - zebrafish
A relatively new animal model for the study of blood
coagulation and related processes is the zebrafish (Danio
rerio). These fish possess a conserved and sophisticated
coagulation system, which in essence follows the same
principles as the system in mammals [30, 31]. Moreover,
the low cost of maintenance and their low turnover time
between subsequent generations make them appealing
for (bio)medical research.
The oligonucleotide of choice in this animal are the
so-called morpholinos, a subclass of ASOs which got
their name because their backbone consists of methyle-
nemorpholine rings [32]. These oligonucleotides do not
degrade the targeted mRNA, but rather block translation
by making the target mRNA inaccessible for ribosomes.
The coagulation factors fibrinogen, prothrombin, and
factor VII have been silenced in vivo using morpholinos.
For fibrinogen, zebrafish produce orthologues for
the three chains of the mature protein, and it has an
in vivo expression pattern comparable to mammals.
Moreover, fibrinogen strands are incorporated in the
(experimental) thrombus of a zebrafish, and upon
morpholino-mediated downregulation of either of the
three orthologues, larvae suffer from intracranial and
intramuscular hemorrhages [33].
Morpholino-mediated downregulation of prothrombin
causes two distinct phenotypes in zebrafish larvae. Some
larvae suffer from serious developmental issues causing
premature death (even before blood flow has developed),
while others develop a bleeding phenotype during a later
stage of embryonic development [34]. These results
recapitulate the hemophilic phenotype that is seen in
experimental mammalian animals with deficiencies of
these factors. Moreover, a microarray analysis was per-
formed on mRNA from zebrafish treated which were
with prothrombin-morpholinos [35]. A total of 63
upregulated or downregulated genes were identified,
although their exact function remains to be determined.
Using coagulation factor VII-specific morpholinos, it
was shown in zebrafish that hepsin plays a crucial role in
activating factor VII [36]. Besides fibrinogen, prothrombin,
and factor VII, more genes involved in hemostasis, such
as von Willebrand factor and genes involved in thrombo-
cyte production and function, have been targeted in zebra-
fish using morpholinos [37–39].
Although translating results from zebrafish to humans
remains difficult due to a wide evolutionary gap between
both species, the presented data imply that using
zebrafish-specific advantages can contribute in unravel-
ing processes of hemostasis, with a clear role for the use
of oligonucleotides as a tool.
siRNAs and ASOs in animal models for
coagulation - mammals
In order to study processes involving coagulation factors,
mammalian animal models, such as mice, rats, and rab-
bits, are genetically closer related to humans. In these
mammals it has been shown that siRNAs and ASOs can
be delivered to the liver in vivo to silence (pre)mRNAs
of proteins produced in hepatocytes [26, 40–42]. Several
genes involved in the extrinsic, common, or anticoagu-
lant pathway of coagulation have been targeted.
Antithrombin, protein C, and protein S are important
natural anticoagulants, and individuals with partial
deficiencies in either of these factors have an increased
risk to develop venous thrombosis, while full deficiency
is rare and very severe or incompatible with life [43].
Genetically modified mice missing either of these antico-
agulants die in utero because of thrombotic complications.
However, using siRNAs, the anticoagulants antithrombin
or protein C can be silenced transiently in adult mice to
study them in a less anticoagulant environment. When
both natural anticoagulants are silenced simultaneously
mice develop spontaneous venous thrombosis, a pheno-
type which is characterized by the formation of fibrin-rich
thrombi in the head and rapid consumption of coagula-
tion factors [44].
This mouse model allowed studying factors involved
in (experimental) venous thrombosis pathophysiology.
Platelets appeared to be crucial for spontaneous venous
thrombosis to occur, whereas neutrophils were not rate
limiting, and lowering of plasma coagulation factor XII
surprisingly seemed to aggravate rather than rescue the
thrombotic phenotype [45].
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Oligonucleotides can be used as a tool to study the
effect of transiently silencing a certain gene, to bypass
early lethality. An interesting example of such an
approach has been described for studying the role of
(pro)thrombin in Sickle cell disease (SCD) [46]. Genetic-
ally modified mice missing prothrombin are not viable
due to fatal prenatal bleeding complications, so the au-
thors were forced to choose another approach. Using
prothrombin-specific designed gapmers (a class of ASOs
where the internal sequence block is protected from nu-
clease degradation by artificially modified ribonucleotide
monomers) prothrombin was transiently silenced SCD
mice. It was shown that in SCD mice reduced levels of
prothrombin lowered inflammation and endothelial cell
dysfunction, and improved multiple SCD-associated
organ pathologies and overall survival. These data imply
that targeting a single coagulation factor i.e., prothrom-
bin can ameliorate SCD pathology.
Using a comparable approach, the transcription factors
hepatocyte nuclear factor 4α and CCAAT/enhancer-
binding protein α were silenced using siRNAs, to study
their regulatory role in the transcription of coagulation
genes, demonstrating that by means of siRNAs the role
of a gene in a certain process can be simply and rapidly
unraveled [47].
Oligonucleotides as therapeutics – animal studies
Besides using oligonucleotides as a tool for the study of
gene function, they are also candidate therapeutics in
the field of blood coagulation. All key proteins (with the ex-
ception of tissue factor and membrane bound receptors
such as thrombomodulin, endothelial protein C receptor,
and protease-activated receptors) are predominantly
expressed in the liver. Moreover, a major advantage of
using oligonucleotide drugs over other more conventional
therapeutic strategies lies in the drugs’ target: (pre)mRNAs.
Targeting proteins is complex due to their three-
dimensional structure and small conformational differences
which can cause complete loss of function of a drug, while
(pre)mRNAs just differ in their gene-specific sequence.
This means that conventional (“protein-based”) drugs have
to undergo an elaborate screening process for compounds
that inhibit the protein of interest in both experimental ani-
mals (during preclinical studies) and humans (actual trials),
while for RNA-based drugs solely the oligonucleotide
sequence needs to be adjusted. Moreover, oligonucleotide
drugs can stably repress protein levels over the course of
several weeks. In addition, oligonucleotides are not
expected to become subject to an immunogenic response,
inhibitors, or resistance during therapy.
The fundamental process of blood coagulation and the
disease of venous thrombosis can be effectively inhibited
in humans by using agents such as vitamin K antago-
nists, heparins, and the new generation of direct oral
anticoagulants [48, 49]. All these therapeutics target
components of the common pathway of coagulation.
Outside the common pathway, coagulation factor IX
might be an interesting candidate to target for the pre-
vention of thrombosis. With an siRNA against this co-
agulation factor, it has been shown in rats that protein
activity can be reduced with 50-99%. This reduced activ-
ity prevented experimental thrombosis without causing a
bleeding phenotype. Over 99% inhibition of factor IX ac-
tivity resulted in a bleeding phenotype, similar to factor
IX deficient rats [50]. This observation makes an “inter-
mediate” dose of siRNAs against factor IX (resulting in
50–99% reduction of activity) potentially interesting for
therapeutic purposes.
Although targeting individual components from the
coagulation cascade proved effective in preventing
thrombosis, bleeding often remains a clinically relevant
side effect. To circumvent this problem, coagulation
factors XI and XII, both involved in the intrinsic, or
contact-activation, pathway of coagulation have been
introduced to target for preventing venous thrombosis
[51–53]. Based on data derived from mouse studies,
deficiency or transient lowering of factor XI and XII
prevents thrombosis without (severe) bleeding as a side
effect, unlike any other traditional coagulation factor.
These reports coincide with human data, where individ-
uals with a factor XII deficiency do not have a bleeding
tendency, and factor XI deficient patients (although oc-
casionally suffering from mild and injury-related events,
hemophilia C) even seem to be protected from develop-
ing thrombotic events [54–56]. Moreover, both plasma
proteins are exclusively produced in the liver, making
them accessible for oligonucleotide therapy.
Coagulation factor XII is a plasma protease which
upon activation initiates the intrinsic pathway of coagu-
lation. When rats deficient in factor XII were compared
with rats treated with a specific siRNA against factor XII
(99% reduction in plasma factor XII), both showed pro-
tection in arterial as well as in venous thrombosis
models [57]. In rabbits, a factor XII-specific ASO pro-
longed the time to occlusion in a catheter thrombosis
model by 2.2 fold [58]. Comparable thromboprotective
effects were obtained in mouse studies. Specific lowering
of factor XII or (pre)kallikrein (an activator of the zymogen
factor XII) using an ASO, resulted in reduced thrombus
formation models for arterial and venous thrombosis, with-
out a significant effect on normal hemostasis [59].
Coagulation factor XII is not only involved in (experi-
mental) hemostasis, but also in release of bradykinin
from high molecular weight kininogen, an inflammatory
component mediating the dilation of blood vessels. Spe-
cific gain-of-function mutations in factor XII causing in-
creased contact-mediated auto activation, which causes
enhanced release of bradykinin and massive swelling,
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underlies hereditary angioedema type III [60]. Interest-
ingly, experimental data in mice show that upon
lowering factor XII or (pre)kallikrein using a specific
oligonucleotide, certain characteristics associated with
this disease can be prevented, which opens perspectives
for treatment [61–63].
Coagulation factor XI is activated by factor XII
towards activated factor XI. In mice, ASO-mediated
specific and dose-dependent reduction of plasma factor
XI showed an antithrombotic effect in various arterial
and venous thrombosis models [40]. In parallel groups,
mice were treated with either warfarin or enoxaparin, a
commonly used vitamin K antagonist and low molecular
weight heparin, respectively. Although the antithrom-
botic effect was considered equally effective in all
groups, factor XI ASO-treated mice performed signifi-
cantly better in a hepatectomy surgical bleeding model.
In rabbits, lowering of factor XI prolonged the time to
occlusion in a catheter thrombosis model, in a similar
fashion as factor XII [58]. After these promising results,
the role of factor XI and its therapeutic antithrombotic
potential was tested in non-human primates. Again
using mRNA-specific ASOs, it was first shown that
plasma factor XI can be lowered in a dose-dependent
manner without increasing the risk of bleeding [64]. In a
second study, the antithrombotic potential of FXI-ASO
was tested in non-human primates. In an arteriovenous
shunt thrombosis model protection from thrombosis
was reported, which coincided with a decreased throm-
bin generation [65]. These studies formed solid proof to
continue with using an ASO against factor XI in clinical
trials. Interestingly, silencing coagulation factors XI and
XII also attenuated atherothrombosis in mice [66, 67],
which implies that silencing these factors also might be
useful in treating atherothrombotic complications.
Besides targeting procoagulant proteins to prevent
venous thrombosis, targeting anticoagulants might also
be useful in preventing disease, in a situation where the
hemostatic balance has shifted towards bleeding i.e.,
hemophilia. Current therapies to treat hemophilia are
based on administering plasma derived or recombinant
proteins to replace the missing coagulation factors. The
need for developing alternative treatment strategies is
high, since a large portion of treated hemophilia patients
develops inhibitory antibodies against these administered
proteins. A promising approach which likely circum-
vents this problem is by silencing an anticoagulant using
oligonucleotides, which can cause a shift towards a
renewed hemostatic equilibrium. This hypothesis was
tested by targeting antithrombin [68]. When factor VIII-
deficient hemophilic mice were treated with an siRNA
against antithrombin, the hemophilic phenotype disap-
peared in a dose-dependent manner without thrombotic
complications. In the next animal model of choice, non-
human primates (cynomolgus monkeys) with antibody
induced FVIII deficiency, a dose-dependent silencing of
antithrombin was again observed. Moreover, thrombin
generation were restored to normal levels when treating
the monkeys with the siRNA, which opened the perspec-
tive to test this drug in humans.
Oligonucleotides as therapeutics – human studies
Recently, the first oligonucleotide drug targeting speci-
fically the liver has been approved by the United States’
Food and Drug Administration. This therapeutic, an
ASO called mipomersen (Kynamro®), directly targets the
pre-mRNA of apolipoprotein B, which causes a significant
downregulation of the corresponding plasma protein. This
specific downregulation allows more release of very low
density lipoprotein (VLDL) from the liver to the blood-
stream, which will cause a drop of LDL-cholestorol levels
in plasma [69, 70]. This is in line with the concept of the
oligonucleotide drugs, which has been outlined previously.
Mipomersen has been approved to treat homozygous fa-
milial hypercholesterolemia, and the availability of mipo-
mersen is currently being investigated for more risk
groups with high cholesterol levels to protect them from
cardiovascular disease (http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm337195.htm).
The approval of mipomersen might cause a domino
effect for the use of oligonucleotides which target
mRNA in the liver for treating other human diseases:
The first hurdle of safely delivering oligonucleotides to the
liver has been overcome, so by using the same chemical
formulation many more hepatic mRNAs can be targeted,
which is an appealing prospect. Two oligonucleotide drugs
are currently being tested in the field of coagulation, one
for venous thrombosis treatment and one for hemophilia.
Coagulation factor XI has been investigated extensively
in animal models for its role in coagulation, and whether
it can be a therapeutic target to prevent venous throm-
bosis without introducing bleeding as a side effect [71].
Recently, the results of a clinical trial were reported,
where an ASO against factor XI (FXI-ASO) was used for
the prevention of deep-vein thrombosis after knee
arthroplasty [72]. Previously, FXI-ASO was considered
safe to use in humans since no side effects (including
bleeding) were observed in a prior study [73]. When
comparing a high and low dose FXI-ASO with conven-
tional enoxaparin treatment, the bleeding risk was not
significantly different (although less bleeding events were
scored for FXI-ASO patients). Interestingly, treatment of
patients with the low dose of FXI-ASO appeared safe
considering the risk of deep-vein thrombosis, where the
high dose was even considered superior to enoxaparin.
Currently, a phase 2 clinical trial has been completed
in which the efficacy of FXI-ASO in patients with
end-stage renal disease was evaluated, with the
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primary goal to monitor the safety and tolerability of
the ASO (ISIS 416858, Ionis pharmaceuticals).
Significant and dose-dependent reductions in FXI ac-
tivity were observed upon treatment (http://ir.ioni-
spharma.com/phoenix.zhtml?c=222170&p=irol-news
Article&ID=2217775).
As outlined previously, on the other side of the
spectrum hemophilia can be treated by transient lower-
ing of antithrombin, to restore the hemostatic balance.
Currently, a human-specific antithrombin siRNA named
Fitusiran is being tested in phase 1 clinical trials. This
siRNA, amongst others candidate siRNAs which are
tested in clinical trials, is chemically modified to improve
its systemic stability and is conjugated to a GalNAc-
ligand, which allows hepatocyte-specific uptake [17].
The phase 1 clinical trial is done in a diverse group of
individuals, including healthy volunteers, patients with
hemophilia A or B, and with or without inhibitors
against supplemented recombinant proteins [74]. The
goal of this trial is to evaluate the safety and tolerability
of multiple doses of subcutaneously administered Fitu-
siran. Moreover, thrombin generation assays in plasma
derived from hemophilia patients are performed to test
whether they recover towards levels of healthy individ-
uals. Preliminary data show that hemophilia patients did
not develop any serious (thromboembolic) complications
because of the drug. Considering functionality of the
drug, when antithrombin levels were lowered to >75%
thrombin generation peaks were increased in a dose-
dependent manner with 289%. Positive interim results of
two clinical trials (phase 1 and phase 2) for Fiturisan




Hepatic in vivo gene silencing using oligonucleotides has
shown to be specific and rapidly applicable in multiple
animal models. The approach can not only serve as an
alternative for using genetically modified animals (al-
though restricted to the liver), it can also help unraveling
biological processes which cannot be studied otherwise.
Moreover, promising preclinical trials for the develop-
ment of new oligonucleotide drugs to treat thrombosis
and hemophilia have been reported.
Since the introduction of mipomersen in 2013, the
first oligonucleotide drugs are slowly finding their way
towards the clinic (currently, three ASOs and no siRNAs
yet). Together with all the preclinical data, it has been
shown that the process of delivering oligonucleotides to
the liver can be achieved in a safe way (thus far, no spe-
cific toxicities have been observed). Currently, prevent-
ing adverse events (at the injection site or from
infusions) of oligonucleotide drugs remains an important
issue, which means that reducing the dosage of the
drugs is crucial. The dosages can be lowered by, for in-
stance, the conjugation of GalNAc-ligands to oligonucle-
otides to improve cell-specific delivery [22]. When these
delivery and dosage issues can be solved, more clinical
situations will present where using oligonucleotides will
be regarded advantageous over using classical therapies.
Thrombosis and hemophilia are two diseases where
the current treatment can be improved, and the two
drugs which are currently investigated in clinical trials
show promise. An important advantage compared to
current therapies for hemophilia is that the effect of
oligonucleotides remains for a longer time period, in
contrast to the low-interval dosing of conventional treat-
ment. This would mean that patients will go from daily to
monthly treatment. Moreover, hemophilia patients who
develop inhibitors against supplemented factor VIII or IX
will benefit from this novel treatment option, since oligo-
nucleotides will likely not provoke this immune response.
Although the mode of action of oligonucleotides in
humans compared to current therapies can be regarded
as a great benefit, it can be a problem in situations when
rapid reversal of the silenced protein is necessary. In
some cases, singular treatment with recombinant pro-
teins will be a solution, although correct dosing would
be crucial. A more elegant solution would be to use an
oligonucleotide antidote. Recently, it was shown in mice
that upon prothrombin-specific ASO treatment, comple-
mentary sense oligonucleotide antidote (SOAs) reversed
the antithrombotic phenotype by specifically binding of
ASOs intracellularly [75]. Even though these data are
promising, therapeutic usefulness has to be proven for
individual ASOs. Moreover, it has been shown that re-
versal of siRNA therapy is feasible using complementary
high affinity oligonucleotides as a “synthetic target” or
decoy to abrogate silencing activity of antisense-loaded
RISC (Reversir™, http://www.alnylam.com/web/assets/
Reversir_OTS_101315.pdf ). Currently, the strategy has
been reported to be functional for reversal of the effect
of an siRNA against coagulation factor IX. The major
disadvantage of this oligonucleotide-specific approach is
that it may take too long for the antidote to restore
original levels of the initially silenced protein. For this
reason, in the case of a sudden event such as a surgical
intervention, an oligonucleotide-specific antidote may
not be adequate and recombinant proteins or fresh frozen
plasma treatment are still necessary.
In conclusion, in fundamental research oligonucleo-
tides targeting coagulation factors in the liver can serve
multiple purposes, and can improve our understanding
about coagulation biology, in physiology and disease.
Considering oligonucleotide-based silencing of coagula-
tion factors to treat thrombosis or hemophilia, for the
short term, validation studies focused on the safety and
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efficacy of the products for clinical applications look
promising. For the long term, a whole new class of drugs
might enter the market, where oligonucleotides might
have the potency to be delivered to other organs than
the liver, or allow allele-specific silencing. Moreover, an
entire panel of genes could be silenced by including
multiple oligonucleotides in a single treatment. Time
will tell whether the new generation of RNA-targeting
therapeutics can fulfill its promise.
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